Preclinical characteristics of the irreversible pan-HER kinase inhibitor neratinib compared with lapatinib : implications for the treatment of HER2-positive and HER2-mutated breast cancer

• Main Authors: Collins, Denis M., Conlon, Neil T., Kannan, Srinivasaraghavan, Verma, Chandra Shekhar, Eli, Lisa D., Lalani, Alshad S., Crown, John
• Other Authors: School of Biological Sciences
• Format: Article
• Language: English
• Published: 2020
• Subjects: Science::Biological sciences; Tyrosine Kinase Inhibitors; Lapatinib
• Online Access: https://hdl.handle.net/10356/142754
• Institution: Nanyang Technological University

An estimated 15-20% of breast cancers overexpress human epidermal growth factor receptor 2 (HER2/ERBB2/neu). Two small-molecule tyrosine kinase inhibitors (TKIs), lapatinib and neratinib, have been approved for the treatment of HER2-positive (HER2+) breast cancer. Lapatinib, a reversible epidermal g...